News Releases
View printer-friendly version < < backWorldwide sales for the full-year 2018 were
Net earnings and diluted earnings per share for the fourth quarter of 2018 were
Net earnings and diluted earnings per share for the full-year 2018 were
"
Mr. Gorsky continued, "Our performance is the result of our talented
In December, the Company announced a share repurchase program of up to
The Company announced its 2019 full-year guidance for sales of
Segment Sales Performance
Worldwide Consumer sales of
Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by growth in over-the-counter products, including TYLENOL and MOTRIN analgesics and digestive health products; NEUTROGENA and OGX beauty products; and LISTERINE oral care products. Subsequent to the quarter, the Company announced the completion of the acquisition of Ci:z
Worldwide Pharmaceutical sales of
Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by STELARA (ustekinumab) and SIMPONI/SIMPONI ARIA (golimumab), biologics for the treatment of a number of immune-mediated inflammatory diseases, ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer, DARZALEX (daratumumab), for the treatment of patients with multiple myeloma, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer, TREMFYA (guselkumab), for the treatment of adults living with moderate to severe plaque psoriasis, INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), a long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, partially offset by declines in REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, due to biosimilar entrants.
During the quarter, the
A supplemental Biologics License Application was submitted to the
Additionally, the Company entered into a worldwide collaboration and license agreement with argenx BVBA and argenx SE to develop and commercialize cusatuzumab (ARGX-110), an investigational therapeutic antibody that targets CD70, an immune checkpoint implicated in numerous cancers, including hematological malignancies.
Worldwide Medical Devices sales of
Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by electrophysiology products in the Interventional Solutions business; ACUVUE contact lenses and surgical products in the Vision business; wound closure products in the General Surgery business; along with endocutters and biosurgicals in the Advanced Surgery business.
About
At
* Operational sales growth excluding the net impact of acquisitions and divestitures, as well as adjusted net earnings, adjusted diluted earnings per share and operational adjusted diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at www.investor.jnj.com.
Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of
(Unaudited; Dollars in Millions) |
FOURTH QUARTER |
TWELVE MONTHS |
|||||||||||||||||
Percent Change |
Percent Change |
||||||||||||||||||
2018 |
2017 |
Total |
Operations |
Currency |
2018 |
2017 |
Total |
Operations |
Currency |
||||||||||
Sales to customers by |
|||||||||||||||||||
segment of business |
|||||||||||||||||||
Consumer |
|||||||||||||||||||
U.S. |
$ 1,479 |
1,379 |
7.3 |
% |
7.3 |
- |
$ 5,761 |
5,565 |
3.5 |
% |
3.5 |
- |
|||||||
International |
2,057 |
2,161 |
(4.8) |
0.8 |
(5.6) |
8,092 |
8,037 |
0.7 |
1.4 |
(0.7) |
|||||||||
3,536 |
3,540 |
(0.1) |
3.3 |
(3.4) |
13,853 |
13,602 |
1.8 |
2.2 |
(0.4) |
||||||||||
Pharmaceutical |
|||||||||||||||||||
U.S. |
5,936 |
5,776 |
2.8 |
2.8 |
- |
23,286 |
21,474 |
8.4 |
8.4 |
- |
|||||||||
International |
4,254 |
3,905 |
8.9 |
13.7 |
(4.8) |
17,448 |
14,782 |
18.0 |
16.5 |
1.5 |
|||||||||
10,190 |
9,681 |
5.3 |
7.2 |
(1.9) |
40,734 |
36,256 |
12.4 |
11.8 |
0.6 |
||||||||||
Medical Devices |
|||||||||||||||||||
U.S. |
3,214 |
3,314 |
(3.0) |
(3.0) |
- |
12,837 |
12,824 |
0.1 |
0.1 |
- |
|||||||||
International |
3,454 |
3,660 |
(5.6) |
(1.4) |
(4.2) |
14,157 |
13,768 |
2.8 |
1.9 |
0.9 |
|||||||||
6,668 |
6,974 |
(4.4) |
(2.2) |
(2.2) |
26,994 |
26,592 |
1.5 |
1.1 |
0.4 |
||||||||||
U.S. |
10,629 |
10,469 |
1.5 |
1.5 |
- |
41,884 |
39,863 |
5.1 |
5.1 |
- |
|||||||||
International |
9,765 |
9,726 |
0.4 |
5.1 |
(4.7) |
39,697 |
36,587 |
8.5 |
7.7 |
0.8 |
|||||||||
Worldwide |
$ 20,394 |
20,195 |
1.0 |
% |
3.3 |
(2.3) |
$ 81,581 |
76,450 |
6.7 |
% |
6.3 |
0.4 |
Johnson & Johnson and Subsidiaries |
|||||||||||||||||||
Supplementary Sales Data |
|||||||||||||||||||
(Unaudited; Dollars in Millions) |
FOURTH QUARTER |
TWELVE MONTHS |
|||||||||||||||||
Percent Change |
Percent Change |
||||||||||||||||||
2018 |
2017 |
Total |
Operations |
Currency |
2018 |
2017 |
Total |
Operations |
Currency |
||||||||||
Sales to customers by |
|||||||||||||||||||
geographic area |
|||||||||||||||||||
U.S. |
$ 10,629 |
10,469 |
1.5 |
% |
1.5 |
- |
$ 41,884 |
39,863 |
5.1 |
% |
5.1 |
- |
|||||||
Europe |
4,730 |
4,728 |
0.0 |
3.9 |
(3.9) |
18,753 |
17,126 |
9.5 |
6.2 |
3.3 |
|||||||||
Western Hemisphere excluding U.S. |
1,456 |
1,519 |
(4.1) |
7.7 |
(11.8) |
6,113 |
6,041 |
1.2 |
8.2 |
(7.0) |
|||||||||
Asia-Pacific, Africa |
3,579 |
3,479 |
2.9 |
5.8 |
(2.9) |
14,831 |
13,420 |
10.5 |
9.4 |
1.1 |
|||||||||
International |
9,765 |
9,726 |
0.4 |
5.1 |
(4.7) |
39,697 |
36,587 |
8.5 |
7.7 |
0.8 |
|||||||||
Worldwide |
$ 20,394 |
20,195 |
1.0 |
% |
3.3 |
(2.3) |
$ 81,581 |
76,450 |
6.7 |
% |
6.3 |
0.4 |
Johnson & Johnson and Subsidiaries |
|||||||||
Condensed Consolidated Statement of Earnings |
|||||||||
(Unaudited; in Millions Except Per Share Figures) |
FOURTH QUARTER |
||||||||
2018 |
2017* |
Percent |
|||||||
Percent |
Percent |
Increase |
|||||||
Amount |
to Sales |
Amount |
to Sales |
(Decrease) |
|||||
Sales to customers |
$ 20,394 |
100.0 |
$ 20,195 |
100.0 |
1.0 |
||||
Cost of products sold |
6,961 |
34.1 |
7,259 |
36.0 |
(4.1) |
||||
Gross Profit |
13,433 |
65.9 |
12,936 |
64.0 |
3.8 |
||||
Selling, marketing and administrative expenses |
5,991 |
29.4 |
6,045 |
29.9 |
(0.9) |
||||
Research and development expense |
3,224 |
15.8 |
3,643 |
18.1 |
(11.5) |
||||
In-process research and development |
- |
- |
408 |
2.0 |
|||||
Interest (income) expense, net |
54 |
0.3 |
189 |
0.9 |
|||||
Other (income) expense, net |
978 |
4.8 |
(53) |
(0.3) |
|||||
Restructuring |
64 |
0.3 |
144 |
0.7 |
|||||
Earnings before provision for taxes on income |
3,122 |
15.3 |
2,560 |
12.7 |
22.0 |
||||
Provision for taxes on income |
80 |
0.4 |
13,273 |
65.7 |
N/M |
||||
Net earnings/(Loss) |
$ 3,042 |
14.9 |
$ (10,713) |
(53.0) |
N/M |
||||
Net earnings/(Loss) per share (Diluted/Basic)** |
$ 1.12 |
$ (3.99) |
N/M |
||||||
Average shares outstanding (Diluted/Basic)** |
2,724.0 |
2,684.9 |
|||||||
Effective tax rate |
2.6 |
% |
518.5 |
% |
|||||
Adjusted earnings before provision for taxes and net earnings (1) |
|||||||||
Earnings before provision for taxes on income |
$ 6,046 |
29.6 |
$ 5,251 |
26.0 |
15.1 |
||||
Net earnings |
$ 5,372 |
26.3 |
$ 4,777 |
23.7 |
12.5 |
||||
Net earnings per share (Diluted) |
$ 1.97 |
$ 1.74 |
13.2 |
||||||
Average shares outstanding (Diluted)*** |
2,724.0 |
2,740.7 |
|||||||
Effective tax rate |
11.1 |
% |
9.0 |
% |
|||||
* 2017 Statement of Earnings line items have been restated to reflect impact of ASU 2017-07 |
|||||||||
** In 2017 basic shares are used to calculate loss per share as use of diluted shares when in a loss position would be anti-dilutive |
|||||||||
*** In 2017 difference of 55.8 shares due to anti-dilutive impact on net loss position |
|||||||||
(1)See Reconciliation of Non-GAAP Financial Measures. |
|||||||||
N/M = Not Meaningful |
Johnson & Johnson and Subsidiaries |
|||||||||
Condensed Consolidated Statement of Earnings |
|||||||||
(Unaudited; in Millions Except Per Share Figures) |
TWELVE MONTHS |
||||||||
2018 |
2017* |
Percent |
|||||||
Percent |
Percent |
Increase |
|||||||
Amount |
to Sales |
Amount |
to Sales |
(Decrease) |
|||||
Sales to customers |
$ 81,581 |
100.0 |
$ 76,450 |
100.0 |
6.7 |
||||
Cost of products sold |
27,091 |
33.2 |
25,439 |
33.3 |
6.5 |
||||
Gross Profit |
54,490 |
66.8 |
51,011 |
66.7 |
6.8 |
||||
Selling, marketing and administrative expenses |
22,540 |
27.6 |
21,520 |
28.1 |
4.7 |
||||
Research and development expense |
10,775 |
13.2 |
10,594 |
13.9 |
1.7 |
||||
In-process research and development |
1,126 |
1.4 |
408 |
0.6 |
|||||
Interest (income) expense, net |
394 |
0.5 |
549 |
0.7 |
|||||
Other (income) expense, net |
1,405 |
1.7 |
(42) |
(0.1) |
|||||
Restructuring |
251 |
0.3 |
309 |
0.4 |
|||||
Earnings before provision for taxes on income |
17,999 |
22.1 |
17,673 |
23.1 |
1.8 |
||||
Provision for taxes on income |
2,702 |
3.3 |
16,373 |
21.4 |
N/M |
||||
Net earnings |
$ 15,297 |
18.8 |
$ 1,300 |
1.7 |
N/M |
||||
Net earnings per share (Diluted) |
$ 5.61 |
$ 0.47 |
N/M |
||||||
Average shares outstanding (Diluted) |
2,728.7 |
2,745.3 |
|||||||
Effective tax rate |
15.0 |
% |
92.6 |
% |
|||||
Adjusted earnings before provision for taxes and net earnings (1) |
|||||||||
Earnings before provision for taxes on income |
$ 26,698 |
32.7 |
$ 24,212 |
31.7 |
10.3 |
||||
Net earnings |
$ 22,315 |
27.4 |
$ 20,040 |
26.2 |
11.4 |
||||
Net earnings per share (Diluted) |
$ 8.18 |
$ 7.30 |
12.1 |
||||||
Effective tax rate |
16.4 |
% |
17.2 |
% |
|||||
* 2017 Statement of Earnings line items have been restated to reflect impact of ASU 2017-07 |
|||||||||
(1)See Reconciliation of Non-GAAP Financial Measures. |
|||||||||
N/M = Not Meaningful |
Johnson & Johnson and Subsidiaries |
|||||||||||||||
Reconciliation of Non-GAAP Financial Measures |
|||||||||||||||
Fourth Quarter |
% Incr. / |
Twelve Months |
% Incr. / |
||||||||||||
(Dollars in Millions Except Per Share Data) |
2018 |
2017 |
(Decr.) |
2018 |
2017 |
(Decr.) |
|||||||||
Earnings before provision for taxes on income - as reported |
$ 3,122 |
2,560 |
22.0 |
% |
$ 17,999 |
17,673 |
1.8 |
% |
|||||||
Intangible asset amortization expense |
1,073 |
1,077 |
4,357 |
2,963 |
|||||||||||
Litigation expense, net |
1,288 |
645 |
1,991 |
1,256 |
|||||||||||
Actelion acquisition related cost |
43 |
217 |
243 |
797 |
|||||||||||
Restructuring/Other(1) |
227 |
284 |
700 |
760 |
|||||||||||
In-process research and development |
- |
408 |
1,126 |
408 |
|||||||||||
Diabetes asset impairment |
- |
35 |
4 |
215 |
|||||||||||
AMO acquisition related cost |
27 |
25 |
109 |
140 |
|||||||||||
Contingent liability reversal |
- |
- |
(184) |
- |
|||||||||||
Unrealized loss/(gain) on securities |
182 |
- |
179 |
- |
|||||||||||
Impact of tax legislation |
72 |
- |
72 |
- |
|||||||||||
Other |
12 |
- |
102 |
- |
|||||||||||
Earnings before provision for taxes on income - as adjusted |
$ 6,046 |
5,251 |
15.1 |
% |
$ 26,698 |
24,212 |
10.3 |
% |
|||||||
Net Earnings/(Loss) - as reported |
$ 3,042 |
(10,713) |
N/M |
% |
$ 15,297 |
1,300 |
N/M |
% |
|||||||
Intangible asset amortization expense |
957 |
926 |
3,888 |
2,481 |
|||||||||||
Litigation expense, net |
1,113 |
506 |
1,722 |
955 |
|||||||||||
Actelion acquisition related cost |
39 |
313 |
232 |
767 |
|||||||||||
Restructuring/Other |
190 |
237 |
585 |
595 |
|||||||||||
In-process research and development |
- |
266 |
859 |
266 |
|||||||||||
Diabetes asset impairment |
- |
(116) |
3 |
4 |
|||||||||||
AMO acquisition related cost |
21 |
(198) |
89 |
116 |
|||||||||||
Contingent liability reversal |
- |
- |
(184) |
- |
|||||||||||
Unrealized loss/(gain) on securities |
143 |
- |
141 |
- |
|||||||||||
Impact of tax legislation(2) |
(137) |
13,556 |
(390) |
13,556 |
|||||||||||
Other |
4 |
- |
73 |
- |
|||||||||||
Net Earnings - as adjusted |
$ 5,372 |
4,777 |
12.5 |
% |
$ 22,315 |
20,040 |
11.4 |
% |
|||||||
Operational Increase |
15.4 |
% |
9.8 |
% |
|||||||||||
Currency Increase/(Decrease) |
(2.9) |
% |
1.6 |
% |
|||||||||||
Diluted Net Earnings/(Loss) per share - as reported |
$ 1.12 |
(3.99) |
N/M |
% |
$ 5.61 |
0.47 |
N/M |
% |
|||||||
Dilutive impact of shares excluded due to net loss position |
- |
0.08 |
- |
- |
|||||||||||
Intangible asset amortization expense |
0.35 |
0.34 |
1.42 |
0.90 |
|||||||||||
Litigation expense, net |
0.41 |
0.19 |
0.63 |
0.35 |
|||||||||||
Actelion acquisition related cost |
0.01 |
0.11 |
0.09 |
0.28 |
|||||||||||
Restructuring/Other |
0.07 |
0.08 |
0.21 |
0.22 |
|||||||||||
In-process research and development |
- |
0.10 |
0.32 |
0.10 |
|||||||||||
Diabetes asset impairment |
- |
(0.04) |
- |
- |
|||||||||||
AMO acquisition related cost |
0.01 |
(0.07) |
0.03 |
0.04 |
|||||||||||
Contingent liability reversal |
- |
- |
(0.07) |
- |
|||||||||||
Unrealized loss/(gain) on securities |
0.05 |
- |
0.05 |
- |
|||||||||||
Impact of tax legislation |
(0.05) |
4.94 |
(0.14) |
4.94 |
|||||||||||
Other |
- |
- |
0.03 |
- |
|||||||||||
Diluted Net Earnings per share - as adjusted |
$ 1.97 |
1.74 |
13.2 |
% |
$ 8.18 |
7.30 |
12.1 |
% |
|||||||
Operational Diluted Net Earnings per share - as adjusted |
1.67 |
7.24 |
|||||||||||||
Impact of currency at 2017 foreign currency exchange rates |
0.05 |
0.07 |
(0.12) |
0.06 |
|||||||||||
Operational Diluted Net Earnings per share - as adjusted |
$ 2.02 |
1.74 |
16.1 |
% |
$ 8.06 |
7.30 |
10.4 |
% |
|||||||
(1) Includes $32M recorded in cost of products sold and $131M recorded in other (income) expense for the fourth quarter 2018, and $42M recorded in cost of products sold |
|||||||||||||||
and $98M recorded in other (income) expense for the fourth quarter 2017. |
|||||||||||||||
Includes $105M recorded in cost of products sold and $344M recorded in other (income) expense for twelve months YTD 2018, and $88M recorded in cost of products sold |
|||||||||||||||
and $363M recorded in other (income) expense for twelve months YTD 2017. |
|||||||||||||||
(2) Includes foreign currency translation |
|||||||||||||||
N/M = Not Meaningful |
Johnson & Johnson and Subsidiaries |
||||||||
Reconciliation of Non-GAAP Financial Measure |
||||||||
Operational Sales Growth Excluding Acquisitions and Divestitures |
||||||||
FOURTH QUARTER 2018 ACTUAL vs. 2017 ACTUAL |
||||||||
Segments |
||||||||
Consumer |
Pharmaceutical |
Medical Devices |
Total |
|||||
Operational % (1) |
||||||||
WW As Reported: |
3.3% |
7.2% |
(2.2)% |
3.3% |
||||
U.S. |
7.3% |
2.8% |
(3.0)% |
1.5% |
||||
International |
0.8% |
13.7% |
(1.4)% |
5.1% |
||||
Wound Care / Other |
||||||||
Compeed |
0.7 |
0.1 |
||||||
U.S. |
0.0 |
0.0 |
||||||
International |
1.2 |
0.3 |
||||||
Beauty |
||||||||
Nizoral |
0.6 |
0.1 |
||||||
U.S. |
0.4 |
0.0 |
||||||
International |
0.8 |
0.2 |
||||||
OTC |
||||||||
Zarbees |
(0.8) |
(0.1) |
||||||
U.S. |
(2.2) |
(0.2) |
||||||
International |
0.0 |
0.0 |
||||||
Diabetes Care |
||||||||
LifeScan |
5.3 |
1.9 |
||||||
U.S. |
3.7 |
1.2 |
||||||
International |
6.8 |
2.7 |
||||||
All Other Acquisitions and Divestitures |
0.0 |
0.0 |
0.2 |
0.0 |
||||
U.S. |
0.0 |
0.0 |
0.3 |
0.1 |
||||
International |
0.0 |
0.0 |
0.0 |
0.0 |
||||
WW Ops excluding Acquisitions and Divestitures |
3.8% |
7.2% |
3.3% |
5.3% |
||||
U.S. |
5.5% |
2.8% |
1.0% |
2.6% |
||||
International |
2.8% |
13.7% |
5.4% |
8.3% |
||||
(1)Operational growth excludes the effect of translational currency |
Johnson & Johnson and Subsidiaries |
||||||||
Reconciliation of Non-GAAP Financial Measure |
||||||||
Operational Sales Growth Excluding Acquisitions and Divestitures |
||||||||
TWELVE MONTHS 2018 ACTUAL vs. 2017 ACTUAL |
||||||||
Segments |
||||||||
Consumer |
Pharmaceutical |
Medical Devices |
Total |
|||||
Operational % (1) |
||||||||
WW As Reported: |
2.2% |
11.8% |
1.1% |
6.3% |
||||
U.S. |
3.5% |
8.4% |
0.1% |
5.1% |
||||
International |
1.4% |
16.5% |
1.9% |
7.7% |
||||
Pulmonary Hypertension |
||||||||
Actelion |
(3.2) |
(1.5) |
||||||
U.S. |
(3.4) |
(1.8) |
||||||
International |
(2.8) |
(1.1) |
||||||
Cardiovascular / Metabolism / Other |
||||||||
Actelion |
(0.2) |
(0.1) |
||||||
U.S. |
(0.1) |
(0.1) |
||||||
International |
(0.2) |
(0.1) |
||||||
Spine & Other |
||||||||
Codman Neuroscience |
0.7 |
0.3 |
||||||
U.S. |
0.5 |
0.2 |
||||||
International |
1.1 |
0.4 |
||||||
Wound Care / Other |
||||||||
Compeed |
0.9 |
0.2 |
||||||
U.S. |
0.0 |
0.0 |
||||||
International |
1.4 |
0.4 |
||||||
Vision |
||||||||
Vision Surgical & Eye Health Business |
(0.7) |
(0.3) |
||||||
U.S. |
(0.7) |
(0.2) |
||||||
International |
(0.8) |
(0.3) |
||||||
Beauty |
||||||||
Nizoral |
0.3 |
0.1 |
||||||
U.S. |
0.2 |
0.0 |
||||||
International |
0.4 |
0.1 |
||||||
OTC |
||||||||
Zarbees |
(0.3) |
0.0 |
||||||
U.S. |
(0.6) |
(0.1) |
||||||
International |
0.0 |
0.0 |
||||||
Diabetes Care |
||||||||
LifeScan |
1.4 |
0.5 |
||||||
U.S. |
0.9 |
0.3 |
||||||
International |
1.8 |
0.7 |
||||||
All Other Acquisitions and Divestitures |
0.1 |
0.0 |
0.1 |
0.0 |
||||
U.S. |
0.0 |
0.0 |
0.2 |
0.0 |
||||
International |
0.1 |
0.0 |
0.0 |
0.0 |
||||
WW Ops excluding Acquisitions and Divestitures |
3.2% |
8.4% |
2.6% |
5.5% |
||||
U.S. |
3.1% |
4.9% |
1.0% |
3.4% |
||||
International |
3.3% |
13.5% |
4.0% |
7.8% |
||||
(1)Operational growth excludes the effect of translational currency |
REPORTED SALES vs. PRIOR PERIOD ($MM) |
|||||||||||||||
FOURTH QUARTER |
TWELVE MONTHS |
||||||||||||||
% Change |
% Change |
||||||||||||||
2018 |
2017 |
Reported |
Operational (1) |
Currency |
2018 |
2017 |
Reported |
Operational (1) |
Currency |
||||||
CONSUMER SEGMENT (2) |
|||||||||||||||
BABY CARE |
|||||||||||||||
US |
$ 116 |
$ 123 |
-5.7% |
-5.7% |
- |
$ 422 |
$ 449 |
-6.0% |
-6.0% |
- |
|||||
Intl |
357 |
367 |
-2.7% |
4.8% |
-7.5% |
1,436 |
1,467 |
-2.1% |
0.8% |
-2.9% |
|||||
WW |
473 |
490 |
-3.5% |
2.1% |
-5.6% |
1,858 |
1,916 |
-3.0% |
-0.8% |
-2.2% |
|||||
BEAUTY |
|||||||||||||||
US |
612 |
596 |
2.7% |
2.7% |
- |
2,403 |
2,335 |
2.9% |
2.9% |
- |
|||||
Intl |
499 |
514 |
-2.9% |
2.4% |
-5.3% |
1,979 |
1,865 |
6.1% |
6.2% |
-0.1% |
|||||
WW |
1,111 |
1,110 |
0.1% |
2.5% |
-2.4% |
4,382 |
4,200 |
4.3% |
4.4% |
-0.1% |
|||||
ORAL CARE |
|||||||||||||||
US |
165 |
156 |
5.8% |
5.8% |
- |
637 |
616 |
3.4% |
3.4% |
- |
|||||
Intl |
234 |
237 |
-1.3% |
3.5% |
-4.8% |
918 |
915 |
0.3% |
0.5% |
-0.2% |
|||||
WW |
399 |
393 |
1.5% |
4.4% |
-2.9% |
1,555 |
1,531 |
1.6% |
1.7% |
-0.1% |
|||||
OTC |
|||||||||||||||
US |
491 |
406 |
20.9% |
20.9% |
- |
1,850 |
1,716 |
7.8% |
7.8% |
- |
|||||
Intl |
657 |
699 |
-6.0% |
-2.0% |
-4.0% |
2,484 |
2,410 |
3.1% |
2.1% |
1.0% |
|||||
WW |
1,148 |
1,105 |
3.9% |
6.4% |
-2.5% |
4,334 |
4,126 |
5.0% |
4.4% |
0.6% |
|||||
WOMEN'S HEALTH |
|||||||||||||||
US |
3 |
3 |
0.0% |
0.0% |
- |
13 |
12 |
8.3% |
8.3% |
- |
|||||
Intl |
254 |
259 |
-1.9% |
7.9% |
-9.8% |
1,036 |
1,038 |
-0.2% |
3.5% |
-3.7% |
|||||
WW |
257 |
262 |
-1.9% |
7.8% |
-9.7% |
1,049 |
1,050 |
-0.1% |
3.5% |
-3.6% |
|||||
WOUND CARE / OTHER |
|||||||||||||||
US |
92 |
95 |
-3.2% |
-3.2% |
- |
436 |
437 |
-0.2% |
-0.2% |
- |
|||||
Intl |
56 |
85 |
-34.1% |
-31.2% |
-2.9% |
239 |
342 |
-30.1% |
-30.2% |
0.1% |
|||||
WW |
148 |
180 |
-17.8% |
-16.4% |
-1.4% |
675 |
779 |
-13.4% |
-13.5% |
0.1% |
|||||
TOTAL CONSUMER |